Evidence map›Paper›PMID 41647717›Full record

ArticleESMO real world data and digital oncology2025

Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study.

L Steventon, S Nicum, K Man, D Dodwell, Z Wang, A Patel, B Pickwell-Smith, L Wei, P Chambers

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

L SteventonResearch Department of Practice and Policy, UCL School of Pharmacy, London, UK.
S NicumUniversity College London Hospital NHS Foundation Trust, London, UK.
K ManResearch Department of Practice and Policy, UCL School of Pharmacy, London, UK.
D DodwellNuffield Department of Population Health, University of Oxford, Oxford, UK.
Z WangNuffield Department of Population Health, University of Oxford, Oxford, UK.
A PatelUniversity College London Hospital NHS Foundation Trust, London, UK.
B Pickwell-SmithLeeds Teaching Hospitals NHS Trust, Leeds, UK.
L WeiResearch Department of Practice and Policy, UCL School of Pharmacy, London, UK.
P ChambersResearch Department of Practice and Policy, UCL School of Pharmacy, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: In advanced ovarian cancer, delayed time to chemotherapy (TTC) has been associated with poorer survival outcomes; evidence is conflicting, however. This study investigated the impact of patient demographic factors on TTC and assessed whether TTC was associated with 5-year overall survival. Materials and methods: A retrospective cohort study was conducted using English national data for women with advanced-stage ovarian cancer (IIB-IV), treated with primary debulking surgery (PDS) or interval debulking surgery (IDS) + adjuvant carboplatin/paclitaxel chemotherapy between 1 January 2014 and 31 December 2019. Cox proportional hazards regression was used to compare the primary outcome of 5-year overall survival between patients treated within ≤6 weeks (0-42 days) or >6 weeks (>42 days) of surgery. Results: A total of 4619 patients were included. Of these, 42% ( Conclusions: Median TTC exceeded 4-week guidance from the European Society of Medical Oncology. TTC >6 weeks was associated with reduced 5-year survival in patients treated with interval surgery, but not primary surgery. Regional disparities in TTC were observed.

Indexed as

adjuvant chemotherapycancerovariansurgerytreatment equity

Identifiers

PMID41647717
PMCPMC12836497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.